News | February 14, 2024
Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
These re-agent and diagnostic test kits come with 99.7% accuracy
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The 200 bedded hospital owned & operated by Alexis
Ayush is expanding beyond wellness to therapeutic wellness
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Subscribe To Our Newsletter & Stay Updated
